Cancer Therapeutics | Oncology Agents | Methods for Diagnostic & Therapeutic Studies | Gastrointestinal Cancers
Observational study describing bevacizumab use and outcomes among metastatic colorectal cancer patients receiving care in the outpatient community in the United States
Eric S Nadler*, Kavita R Sail, Lei Chen, Stephen F Thompson, Michael A Kolodziej
*Corresponding author: Eric S Nadler
Baylor University Medical Center, Dallas, TX, USA
F1000Posters 2012, 3: 154 (poster) [English]
Poster [955.13 KB]
Presented at
American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2012 ,
19 - 21 Jan 2012, 547
This study is a review of the utilization and outcomes of bevacizumab use in metastatic colorectal cancer (mCRC) patients receiving 1st-line (1L) and 2nd-line (2L) treatment in the outpatient community setting in the U.S.
This study reviews previously reported observations from the BRiTE (Bevacizumab Regimens: Investigation of Treatment Effects and Safety) registry, and also evaluates patients treated more recently and in both 1L and 2L settings. The study did not show a significant survival advantage with prolonged use of bevacizumab following progression. Further research is needed to confirm these findings.
This study was sponsored by sanofi-aventis U.S. LLC, Inc., A SANOFI COMPANY. Medical editorial writing assistance was provided by Phase Five Communications Inc. and funded by sanofi-aventis U.S.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
